Loading
Life sciences · Journal article
npj Precision Oncology · September 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract There is a major unmet need to develop therapies for patients whose tumors do not respond to PD-1 blockade. Inhibition of the ATR-mediated DNA replication checkpoint has been reported to augment antitumor immunity, although the underlying mechanisms remain poorly understood, particularly in cGAS-STING-deficient tumors. Here, we investigated the effects of ATR inhibition (ATRi) on tumor immunogenicity in Merkel cell carcinoma (MCC), an aggressive skin cancer commonly driven by Merkel cell polyomavirus (MCPyV). Among 92 primary MCC tumors, Ki-67 positivity was observed in 50% of MCPyV-positive and 83% of MCPyV-negative tumor cells, suggesting reliance on ATR-mediated replication stress responses. Notably, MCC frequently exhibits cGAS-STING deficiency, especially in MCPyV-positive tumors. In representative MCPyV-positive and -negative MCC cell lines, ATRi enhanced cytotoxicity and, alone or combined with low-dose radiation, induced proinflammatory NF-κB transcriptional programs. These included increased expression of MHC class I, antigen-processing machinery, interleukins, chemokines, and interferon-related genes. ATRi also increased surface calreticulin exposure and subsequent phagocytosis by human monocyte-derived macrophages. These findings support ATRi-mediated immune reprogramming in MCC cells through an NF-κB signaling cascade, regardless of cGAS–STING functional status. These observations support clinical evaluation of ATR inhibitors in immunotherapy-refractory disease (NCT05947500) and suggest candidate biomarkers of therapeutic response.